239 related articles for article (PubMed ID: 8190113)
41. Involvement of the conserved acidic amino acid domain of FGF receptor 1 in ligand-receptor interaction.
Chaudhuri MM; Moscatelli D; Basilico C
J Cell Physiol; 1993 Nov; 157(2):209-16. PubMed ID: 8227155
[TBL] [Abstract][Full Text] [Related]
42. Intramolecular interactions in muscarinic acetylcholine receptors studied with chimeric m2/m5 receptors.
Pittel Z; Wess J
Mol Pharmacol; 1994 Jan; 45(1):61-4. PubMed ID: 8302281
[TBL] [Abstract][Full Text] [Related]
43. Testing the specificity of allosteric modulators of muscarinic receptors in phylogenetically closely related histamine H1-receptors.
Franken C; Tränkle C; Mohr K
Naunyn Schmiedebergs Arch Pharmacol; 2000 Feb; 361(2):107-12. PubMed ID: 10685864
[TBL] [Abstract][Full Text] [Related]
44. [3H]N-methylscopolamine dissociation from muscarine receptors affected by low concentrations of allosteric modulators.
Christopoulos A; Mitchelson F
Eur J Pharmacol; 1995 Aug; 290(3):259-62. PubMed ID: 7589221
[TBL] [Abstract][Full Text] [Related]
45. Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors.
Avlani V; May LT; Sexton PM; Christopoulos A
J Pharmacol Exp Ther; 2004 Mar; 308(3):1062-72. PubMed ID: 14711931
[TBL] [Abstract][Full Text] [Related]
46. Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes.
Ellis J; Huyler J; Brann MR
Biochem Pharmacol; 1991 Oct; 42(10):1927-32. PubMed ID: 1741770
[TBL] [Abstract][Full Text] [Related]
47. Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators.
May LT; Lin Y; Sexton PM; Christopoulos A
J Pharmacol Exp Ther; 2005 Jan; 312(1):382-90. PubMed ID: 15333678
[TBL] [Abstract][Full Text] [Related]
48. Distinct kinetic binding properties of N-[3H]-methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain.
Flynn DD; Mash DC
Synapse; 1993 Aug; 14(4):283-96. PubMed ID: 8248852
[TBL] [Abstract][Full Text] [Related]
49. Molecular basis of receptor/G protein coupling selectivity studied by coexpression of wild type and mutant m2 muscarinic receptors with mutant G alpha(q) subunits.
Kostenis E; Conklin BR; Wess J
Biochemistry; 1997 Feb; 36(6):1487-95. PubMed ID: 9063897
[TBL] [Abstract][Full Text] [Related]
50. Gallamine exerts biphasic allosteric effects at muscarinic receptors.
Ellis J; Seidenberg M
Mol Pharmacol; 1989 Feb; 35(2):173-6. PubMed ID: 2918854
[TBL] [Abstract][Full Text] [Related]
51. Stabilization of antagonist binding to cardiac muscarinic acetylcholine receptors by gallamine and other neuromuscular blocking drugs.
Nedoma J; Tucek S; Danilov AF; Shelkovnikov SA
J Pharmacol Exp Ther; 1986 Jan; 236(1):219-23. PubMed ID: 3941394
[TBL] [Abstract][Full Text] [Related]
52. Kinetic studies of co-operativity at atrial muscarinic M2 receptors with an "infinite dilution" procedure.
Christopoulos A; Lanzafame A; Ziegler A; Mitchelson F
Biochem Pharmacol; 1997 Mar; 53(6):795-800. PubMed ID: 9113100
[TBL] [Abstract][Full Text] [Related]
53. Mixed competitive and allosteric antagonism by gallamine of muscarinic receptor-mediated second messenger responses in N1E-115 neuroblastoma cells.
Lee NH; el-Fakahany EE
J Neurochem; 1989 Oct; 53(4):1300-8. PubMed ID: 2549200
[TBL] [Abstract][Full Text] [Related]
54. The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site.
Jacobson MA; Kreatsoulas C; Pascarella DM; O'Brien JA; Sur C
Mol Pharmacol; 2010 Oct; 78(4):648-57. PubMed ID: 20660086
[TBL] [Abstract][Full Text] [Related]
55. The quaternary transformation products of N-(3-chloropropyl)-4-piperidinyl diphenylacetate and N-(2-chloroethyl)-4-piperidinyl diphenylacetate (4-DAMP mustard) have differential affinity for subtypes of the muscarinic receptor.
Ehlert FJ; Oliff HS; Griffin MT
J Pharmacol Exp Ther; 1996 Feb; 276(2):405-10. PubMed ID: 8632303
[TBL] [Abstract][Full Text] [Related]
56. Critical amino acid residues of the common allosteric site on the M2 muscarinic acetylcholine receptor: more similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide.
Huang XP; Prilla S; Mohr K; Ellis J
Mol Pharmacol; 2005 Sep; 68(3):769-78. PubMed ID: 15937215
[TBL] [Abstract][Full Text] [Related]
57. Modes of allosteric interactions with free and [3H]N-methylscopolamine-occupied muscarinic M2 receptors as deduced from buffer-dependent potency shifts.
Schröter A; Tränkle C; Mohr K
Naunyn Schmiedebergs Arch Pharmacol; 2000 Dec; 362(6):512-9. PubMed ID: 11138843
[TBL] [Abstract][Full Text] [Related]
58. Muscarinic cholinergic receptor subtypes in the rat brain. I. Quantitative autoradiographic studies.
Cortés R; Palacios JM
Brain Res; 1986 Jan; 362(2):227-38. PubMed ID: 3942874
[TBL] [Abstract][Full Text] [Related]
59. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist.
Langmead CJ; Fry VA; Forbes IT; Branch CL; Christopoulos A; Wood MD; Herdon HJ
Mol Pharmacol; 2006 Jan; 69(1):236-46. PubMed ID: 16207821
[TBL] [Abstract][Full Text] [Related]
60. Allosteric site in M2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist.
Grossmüller M; Antony J; Tränkle C; Holzgrabe U; Mohr K
Naunyn Schmiedebergs Arch Pharmacol; 2006 Jan; 372(4):267-76. PubMed ID: 16362429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]